#基因治疗/编辑

Today 0 items

Oct 15Thu

Thursday

22:29
biospace.comPickScore6262
FDA's latest rare disease framework seeks to prioritize consistency in flexibility
The FDA launched its Rare Disease Framework Initiative to standardize how clinical trial requirements are applied across rare diseases while tailoring evidence expectations to what small patient populations can realistically generate. Only 5% of an estimated 10,000 rare conditions affecting 30 million Americans have an FDA-approved treatment. The framework builds on programs such as the Rare Disease Innovation Hub, CDER's ARC program and the RDEA pilot, and follows the November 2025 plausible mechanism pathway. The FDA will hold a meeting on Oct. 28 to gather feedback from patients, advocates and industry.
Regulatory #Regulatory #FDA #Rare disease
Why it matters: FDA policy shift sets consistent rules for rare disease drug development, a core issue for sponsors of gene and cell therapies.

Oct 8Thu

Thursday

06:21
fda.govScore4141
Recently Issued Guidance Documents
The FDA has released a set of guidance documents for industry and agency staff issued from July to September 2026. The list includes final guidances on blood collection and storage systems for blood components using the buffy coat method, formal PDUFA meetings, cancer clinical trial eligibility criteria on laboratory values, washout periods and performance status, and FAQs for cellular and gene therapy products. Draft guidances cover premarket approval electronic submission templates, potency assessment of active immunotherapy products, container closure systems for drugs, biologicals and biosimilars.
Regulatory #Policy & payers #Gene therapy & editing #Immunotherapy

Oct 5Mon

Monday

18:00
nature.comPickScore7373
Gene therapy for rare lysosomal storage disorder nabs FDA approval
The FDA has approved Ultragenyx Pharmaceutical's gene therapy rebisufligene etisparvovec (Fayuvi) for paediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A. It is the first FDA-approved treatment option for this rare neurodegenerative lysosomal storage disorder.
Regulatory #Regulatory #Gene therapy & editing #Rare disease
Why it matters: First FDA-approved therapy for a rare neurodegenerative lysosomal storage disorder.

Sep 30Wed

Wednesday

00:51
biospace.comPickScore4545
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat
The FDA approved Ultragenyx's Fayuvi for Sanfilippo syndrome type A, the first-ever treatment for that condition, shortly after approving the company's first gene therapy, Genglycos, for glycogen storage disease type Ia; each approval came with a priority review voucher worth as much as $200 million. The wins follow the Phase 3 Asire trial failure of apazunersen in Angelman syndrome, which cut the stock nearly 50%, and a January failure of setrusumab in osteogenesis imperfecta that erased $1 billion in value. CEO Emil Kakkis says Ultragenyx will implement significant expense reductions while keeping the setrusumab program and awaiting an upcoming Angelman readout.
Regulatory #Regulatory #Gene therapy & editing #Rare disease
Why it matters: Two rare-disease approvals including a first Sanfilippo treatment come amid Phase 3 failures forcing cost cuts at Ultragenyx.
00:51
endpoints.newsPickScore6060
Nonprofits' gene therapy for rare immune disease will cost $3.25M
Two nonprofits are launching their gene therapy Waskyra, which won FDA approval at the end of last year, with a list price of $3.25 million. The therapy treats a rare immune disease. Further details of the launch are behind the paywall.
Regulatory #Regulatory #Gene therapy & editing #Rare disease
Why it matters: First gene therapy launched by nonprofits priced at $3.25 million for a rare immune disease.

Sep 19Sat

Saturday

06:13
BioCenturyPickScore6969
Ultragenyx wins first approval for MPS IIIA, closing a bumpy four-year path
FDA granted Ultragenyx traditional approval for rebisufligene etisparvovec, now Fayuvi, the first treatment for Sanfilippo syndrome Type A (MPS IIIA). CBER approved the gene therapy on clinical evidence that treated children maintained or improved cognitive function versus an untreated natural-history cohort, rather than on CSF heparan sulfate as a surrogate endpoint. The outcome exceeds the accelerated approval Ultragenyx had sought in its original application and resubmission, while CBER's biomarker stance remains unresolved.
Regulatory #Regulatory #Rare disease #Gene therapy & editing
Why it matters: First therapy approved for MPS IIIA and an FDA traditional approval relying on external controls.

Sep 18Fri

Friday

07:55
STAT NewsScore5757
STAT+: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease
The FDA approved Fayuvi, a gene therapy developed by Ultragenyx for Sanfilippo syndrome type A, an ultra-rare disease sometimes called childhood Alzheimer's. It is the first drug specifically approved for the condition. Ultragenyx did not immediately release a price.
Regulatory #Regulatory #FDA #Gene therapy & editing
02:26
fda.govPickScore7070
FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time intravenous AAV9 gene therapy from Ultragenyx Pharmaceutical, as the first treatment for pediatric patients with mucopolysaccharidosis type IIIA, or Sanfilippo syndrome type A. In an open-label, single-arm multicenter study, treated patients aged 2 to 5 maintained or improved cognitive scores versus an untreated historical control. Patients receive corticosteroids from one day before infusion through at least eight weeks after, with warnings including thrombotic microangiopathy.
Regulatory #Regulatory #Gene therapy & editing #Rare disease
Why it matters: First FDA-approved therapy for a rare pediatric neurodegenerative disease with no prior disease-altering treatment.

Aug 20Thu

Thursday

10:36
fiercepharma.comPickScore8282
Ultragenyx, after FDA speed bump, lands 1st gene therapy nod with green light in glycogen storage disease
The FDA granted accelerated approval to Ultragenyx's AAV gene therapy pariglasgene brecaparvovec-opnr, brand name Genglycos, for adults and children over 8 with glycogen storage disease type Ia. In the phase 3 GlucoGene study, the one-time AAV8 therapy cut daily cornstarch intake by a mean 31% from baseline versus placebo over 48 weeks. Ultragenyx, which also received a priority review voucher, must provide two years of safety and efficacy data on 50 treated and 20 control patients; it awaits a Sept. 19 decision on UX1111.
Regulatory #Regulatory #Gene therapy & editing #Rare disease
Why it matters: First FDA gene therapy approval for Ultragenyx in an ultrarare disease, with a launch and confirmatory commitments following.
05:33
fda.govPickScore6969
FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia
The FDA granted accelerated approval to Ultragenyx Pharmaceutical's Genglycos (pariglasgene brecaparvovec-opnr), a one-time AAV8 gene therapy and the first approved treatment for glycogen storage disease type Ia in patients aged 8 and older. In a 48-week randomized placebo-controlled study, patients achieved a statistically significant 31% mean reduction in daily cornstarch intake, the primary endpoint. The manufacturer must complete additional trials to confirm effectiveness, and the label warns of anaphylaxis, liver toxicity, adrenal insufficiency and tumorigenicity risk.
Regulatory #Regulatory #Gene therapy & editing #Rare disease
Why it matters: FDA cleared the first therapy for glycogen storage disease type Ia under the accelerated pathway.

Aug 14Fri

Friday

19:17
FierceBiotechScore4949
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
Two patient deaths after high-dose gene therapies delivered by viral vectors have drawn international scrutiny of China's investigator-initiated trial (IIT) framework. Both cases involved severe immune reactions, and neither death was disclosed, pointing to gaps in oversight and transparency. The failures raise questions about whether the alternative regulatory path can be trusted.
Regulatory #Policy & payers #Gene therapy & editing #NMPA